ACE is a multi-centre proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069,
administered in combination with enzalutamide, in patients with metastatic castration
resistant prostate cancer(mCRPC). The investigators will be investigating the safety and
toxicity of the combination.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Collaborators:
Astellas Pharma Inc AstraZeneca Prostate Cancer UK